Core Viewpoint - AllianceBernstein Holding L.P. is recognized as one of the most undervalued financial stocks, with a notable increase in assets under management (AUM) and strong performance in various investment areas [1][2]. Group 1: Financial Performance - As of February 2026, AllianceBernstein's AUM rose to $880 billion, up from $875 billion at the end of January, reflecting a 0.6% increase driven by market appreciation, despite modest net outflows [1]. - The company reported Q4 adjusted EPS of 96 cents, surpassing the consensus estimate of 92 cents, with revenue reaching $1.22 billion compared to the consensus of $956.06 million [2]. - In 2025, AllianceBernstein achieved a record AUM of $867 billion and generated over $140 billion in sales, despite experiencing net outflows in active equities [2]. Group 2: Strategic Insights - CEO Seth Bernstein highlighted 2025 as a year of disciplined execution and strategic progress, emphasizing the firm's efforts to broaden its platform and deepen client relationships [2]. - The firm noted significant organic growth in areas such as ultra-high-net-worth, insurance, separately managed accounts, active ETFs, and private markets, with private markets AUM increasing by 18% year over year to reach $82 billion [2]. Group 3: Market Position - Evercore ISI adjusted its price target for AllianceBernstein to $41 from $43 while maintaining an Outperform rating, reflecting a reassessment of the asset manager's flows for February and Q1 [2]. - AllianceBernstein operates as a publicly owned investment manager, providing services to a diverse range of clients including investment companies, pension plans, banks, and individuals [3].

Core Insights - Financial stocks are currently undervalued despite strong credit conditions and improving profitability, with many trading below broader market valuation multiples [2][6] - The financial sector is shifting towards operational precision and efficiency rather than just balance-sheet size, as highlighted by McKinsey & Company's analysis [3] - Institutional investors are identifying attractive entry points in financial equities, with many companies trading below long-term historical averages [4] Valuation and Investment Trends - Valuation discipline is crucial for long-term investors, as emphasized by J.P. Morgan Asset Management, indicating that buying fundamentally sound companies at discounted prices can enhance long-term performance [5] - The financial sector, previously overshadowed by technology gains, now presents compelling investment opportunities due to strong capital positions and improving earnings dynamics [6] Methodology for Stock Selection - The selection of undervalued financial stocks was conducted using the Finviz screener, focusing on those trading below a forward P/E of 15 and having recent noteworthy developments [8] - The strategy of imitating top hedge fund stock picks has shown significant outperformance, with a reported return of 498.7% since May 2014 [9] Company-Specific Insights - **AllianceBernstein Holding L.P. (NYSE:AB)**: Reported a 0.6% increase in assets under management (AUM) to $880 billion in February 2026, driven by market appreciation [11] - The company achieved Q4 adjusted EPS of 96 cents, exceeding the consensus estimate, with revenue of $1.22 billion compared to the consensus of $956.06 million [13] - **Bank of America Corporation (NYSE:BAC)**: Anticipates a 7% year-over-year increase in first-quarter net interest income and a 10% rise in investment banking revenue [15] - The bank plans to invest approximately $25 billion into private-credit transactions to expand its direct-lending platform [16]

Core Insights - AllianceBernstein L.P. and AllianceBernstein Holding L.P. reported a preliminary increase in assets under management (AUM) to $880 billion as of February 28, 2026, up from $875 billion at the end of January 2026, representing a 0.6% increase driven by market appreciation, despite modest net outflows [1][1][1] AUM Breakdown - The AUM increase was attributed to various channels, with Private Wealth and Institutional channels experiencing net inflows, while the Retail channel faced net outflows during February 2026 [1][1] - The total AUM composition as of February 28, 2026, included: - Total Equity: $792 billion - Actively Managed: $276 billion - Passive: $294 billion - Total Fixed Income: $124 billion - Taxable: $123 billion - Tax-Exempt: $160 billion - Alternatives/Multi-Asset Solutions: $201 billion - The total AUM as of January 31, 2026, was $875 billion, with a similar breakdown [1][1][1]

Core Insights - AllianceBernstein Holding achieved a record $867 billion in assets under management (AUM) by the end of 2025, driven by market appreciation and strong performance in specialized segments [1][7] - The firm experienced $9.4 billion in total active net outflows for the year, primarily due to $22.5 billion in redemptions from active equities and a decline in taxable fixed-income demand [2] - The adjusted operating margin expanded to 33.7% in 2025, with a focus on scaling high-growth platforms and exceeding private market AUM targets of $90 to $100 billion by 2027 [3] Financial Performance - The Bernstein Private Wealth business reached $156 billion in AUM, contributing 37% of firmwide revenues [1] - The private markets platform grew 18% to $82 billion, while the active ETF suite saw 65% organic growth, ending the year with $14 billion in assets [1] - Q4 adjusted earnings fell 9% year-over-year to $0.96 per unit, and full-year performance fees dropped 24% to $172 million [2] Strategic Focus - The company aims to maintain its adjusted operating margin while expanding its private credit and international ETF franchises [3] - Management expressed ambition to exceed private market AUM targets through continued growth in high-potential areas [3]

Core Insights - AB Science has identified a plasma biomarker that indicates the activity of masitinib in treating Amyotrophic Lateral Sclerosis (ALS) and can identify patients with pro-inflammatory microglia, which are targeted by masitinib [1][2] - This biomarker is also applicable to progressive forms of Multiple Sclerosis (MS) and Alzheimer's disease, potentially enhancing treatment response identification and registration chances in neurodegenerative diseases [1][2] Biomarker Characteristics - The biomarker is blood-based, easy to collect, and can be accurately evaluated using ELISA [4] - It is produced by pro-inflammatory microglia, activates microglia and astrocytes, and contributes to a neuroinflammation feedback loop [4] - It is predictive of survival in ALS, potentially explaining why masitinib could extend survival in specific patients [4] Clinical Development - The biomarker will be introduced in the phase 3 program of masitinib for ALS, progressive MS, and Alzheimer's disease to validate its mechanism of action and clinical relevance [3] - Once validated, it could facilitate patient registration by determining the best responders to treatment and serve as a surrogate endpoint of efficacy [3] Regulatory Context - The FDA encourages the incorporation of exploratory biomarkers in all phases of ALS drug development, which may lead to discussions on surrogate endpoints for accelerated approval [3]

Assets Under Management (AUM) - Total Assets Under Management (AUM) reached $866.9 billion as of December 31, 2025, an increase of $74.7 billion, or 9.4%, driven by market appreciation of $86.0 billion, partially offset by net outflows of $11.3 billion[186]. - Institutional AUM increased by $32.8 billion, or 10.2%, to $354.2 billion, with gross sales rising to $26.7 billion from $13.0 billion in 2024[187]. - Retail AUM grew by $22.1 billion, or 6.6%, to $356.4 billion, despite net outflows of $9.1 billion and a decrease in gross sales from $99.9 billion in 2024 to $90.2 billion in 2025[188]. - Private Wealth Management AUM increased by $19.8 billion, or 14.4%, to $156.3 billion, supported by market appreciation of $17.7 billion and net inflows of $2.4 billion[189]. - Total assets under management reached $866.9 billion in 2025, reflecting a 9.4% increase from $792.2 billion in 2024[220]. - The Institutional channel's average AUM increased by $14.7 billion, or 4.5%, to $337.6 billion in 2025, with ending AUM rising by $32.8 billion, or 10.2%, to $354.2 billion[227]. - The Retail channel's average AUM grew by $28.2 billion, or 8.9%, to $343.5 billion in 2025, with ending AUM increasing by $22.1 billion, or 6.6%, to $356.4 billion[229]. - The Private Wealth Management channel's average AUM increased by $14.6 billion, or 11.3%, to $144.9 billion in 2025, with ending AUM rising by $19.8 billion, or 14.4%, to $156.3 billion[231]. Financial Performance - Net revenues for 2025 were $4.5 billion, an increase of $55.5 million, or 1.2%, primarily due to higher investment advisory base fees of $175.1 million[191]. - Operating income decreased by $73.6 million, or 6.5%, to $1.1 billion, with the operating margin declining to 23.0% from 24.7% in 2024[193]. - Net income attributable to AB Unitholders was $982.5 million in 2025, a decrease of 16.3% compared to $1.2 billion in 2024[206]. - AB Holding's net income for 2025 was $299.8 million, a decrease from $423.4 million in 2024, while adjusted net income increased to $336.9 million from $370.8 million in 2024[212]. - The adjusted net income per AB Holding Unit for 2025 was $3.33, compared to $3.25 in 2024[212]. - Net income for 2025 was $299,836,000, compared to $423,374,000 in 2024, reflecting a decline of approximately 29.2%[366]. - Comprehensive income for 2025 was $323,396, down from $423,994 in 2024, reflecting a decline of 23.7%[368]. Expenses and Cash Flow - Operating expenses rose to $3.5 billion, an increase of $129.1 million, or 3.9%, driven by higher promotion and servicing expenses[192]. - Cash provided by operating activities increased to $352.4 million in 2025 from $340.5 million in 2024, primarily due to higher cash distributions from AB of $8.8 million[214]. - Cash distributions to Unitholders increased to $352.4 million in 2025, up from $340.5 million in 2024, driven by higher distributions of $11.2 million[216]. - Net cash provided by operating activities was $1.0 billion in 2025, down from $1.4 billion in 2024, primarily due to a decrease in accounts payable and accrued liabilities[7]. - Total expenses for 2025 increased by 3.9% to $3,480.2 million compared to $3,351.1 million in 2024[1]. Market and Investment Performance - Absolute investment returns for fixed income services showed an 8.86% return for 1 year, outperforming the Bloomberg Barclays U.S. Aggregate Index by 1.56%[233]. - The company reported a significant increase in market appreciation across all channels, contributing to overall AUM growth despite net outflows in certain segments[227]. - Investment advisory and services fees increased by $89.4 million, or 2.6%, in 2025, primarily due to a $175.1 million increase in base fees[272]. - Performance-based fees decreased by $85.7 million, or 31.6%, in 2025, mainly due to lower fees from several funds[273]. - Dividend and interest income decreased by $24.9 million, or 15.1%, in 2025, due to lower interest earned on U.S. Treasury Bills[281]. - Investment losses totaled $30.8 million in 2025, compared to a loss of $13.5 million in 2024[285]. Joint Ventures and Partnerships - AB's joint venture with Societe Generale resulted in a cash payment of $304.0 million to equalize contributions, with AB retaining a 49% interest in the North America joint venture[201]. - The anticipated capital from EQH's insurance subsidiaries is expected to accelerate growth in AB's private alternatives business, enhancing overall performance[198]. - The company plans to fully divest from joint ventures, with income or loss from these investments recorded as equity method investment income (loss) starting April 1, 2024[252]. Liquidity and Capital Management - AB Holding has no liquidity risk as it only pays distributions to Unitholders based on the cash flow received from AB[217]. - The company believes its financial condition and access to capital markets will provide adequate liquidity for its general business needs[315]. - The company maintains an $800 million committed, unsecured senior revolving credit facility, which was amended on August 5, 2025[317]. Other Financial Metrics - The operating margin for 2025 was 23.0%, down from 24.7% in 2024 and up from 19.1% in 2023[236]. - Cash distributions per AB Unit increased by 3.1% to $3.71 in 2025, compared to $3.60 in 2024 and $3.00 in 2023[236]. - The company recorded an impairment charge of $4.0 million related to a smaller historical acquisition in 2025[258]. - The company issued 132,079 AB Holding Units for long-term incentive compensation plan awards in 2025, up from 115,640 in 2024[372].

Core Insights - AllianceBernstein L.P. reported a preliminary increase in assets under management to $875 billion as of January 31, 2026, up from $867 billion at the end of December 2025, reflecting a 1% month-over-month growth driven by market appreciation [1][1][1] Assets Under Management Breakdown - The total assets under management include: - Private: $52 billion - Institutions: $167 billion - Retail: $61 billion - Wealth: $280 billion - Total Equity: $812 billion - Total Fixed Income: $121 billion - Alternatives/Multi-Asset Solutions: $156 billion - The total equity increased from $810 billion to $812 billion, while total fixed income saw a slight increase from $121 billion to $121 billion [1][1][1] Net Outflows - The increase in assets was partially offset by net outflows concentrated in the Retail and Institutional channels, with Private Wealth also experiencing slight outflows [1][1][1] Company Overview - AllianceBernstein is a leading global investment management firm that provides diversified investment services to institutional investors, individuals, and private wealth clients across major world markets [1][1][1]

Core Insights - Albert Anthony is a Croatian-American business author and analyst contributing to Seeking Alpha with over 1,000 followers [1] - He has authored a book titled "Real Estate Investment Trusts (REITs): A Fundamental Analysis (2026 Edition)" available on Amazon [1] - Anthony has a background in business and information systems, having worked at Charles Schwab in the IT department [1] - He operates his own boutique equities research firm, Albert Anthony & Company, remotely [1] - The author has participated in numerous business and innovation conferences and has hosted a program for Online Live TV Croatia [1] - He holds a B.A. in Political Science and various certifications including Microsoft Fundamentals and Risk Management specialization from CFI [1] - Anthony is also active on YouTube discussing REITs and is an investor in REIT stocks [1] Company and Industry Summary - Albert Anthony & Company is a Texas-registered business focused on equities research [1] - The firm provides general market commentary and research based on publicly available data [1] - The author does not engage with non-publicly traded companies, small cap stocks, or startup CEOs [1]

Core Viewpoint - AB Science has received FDA's Minor Use in Major Species (MUMS) designation for Masivet® to treat canine mast cell tumors, which is expected to facilitate its development and commercialization in the USA [1][3][4]. Company Overview - AB Science is a pharmaceutical company founded in 2001, specializing in the research, development, and commercialization of protein kinase inhibitors (PKIs) targeting diseases with high unmet medical needs [7][8]. - The company is headquartered in Paris, France, and is listed on Euronext Paris [8]. Product Information - Masivet® is a targeted therapy that inhibits juxtamembrane mutations of c-kit, the main driver of dog mast cell tumors [2]. - The MUMS designation provides seven years of exclusive marketing rights upon approval and eligibility for grants to support the approval process [3]. Market Potential - Masivet® is already registered and profitable in Europe but not yet in the USA; the MUMS status is seen as a significant encouragement for its development in the US market [4]. - AB Science aims to expand its animal health franchise, with expectations that EBITDA from this segment will help cover fixed costs and contribute to the company's financial stability [4]. Global Expansion Plans - The company is in discussions for distribution and commercialization agreements in various regions, including Europe (Norway, Denmark, Sweden, Finland, Lithuania), LATAM (Brazil, Argentina, Mexico), Asia (Japan, Taiwan), MENA regions, and South Africa [5]. - There is a global demand for Masivet, with positive feedback from pet owners and veterinarians regarding its safety and effectiveness [6].

Core Viewpoint - AllianceBernstein Holding L.P. demonstrated strong financial performance in its latest earnings report, surpassing revenue and earnings estimates while managing a significant amount of assets despite facing net outflows [1][2][6] Financial Performance - The company reported an earnings per share (EPS) of $0.96, exceeding the estimated $0.92 [1][6] - Revenue was approximately $957.3 million, slightly above the forecast of $956.1 million [2][6] - The GAAP diluted net income was $0.90 per unit, with an adjusted diluted net income of $0.96 per unit [2] Assets Under Management - AllianceBernstein closed the year with a record $867 billion in assets under management [3][6] Net Outflows - The company faced $9.4 billion in net outflows, primarily due to $22.5 billion in net redemptions [4][6] Growth Areas - Despite the outflows, the company achieved targeted organic growth in areas such as ultra-high-net-worth, insurance, separately managed accounts (SMAs), active ETFs, and private markets [4] Financial Metrics - The company has a price-to-earnings (P/E) ratio of approximately 14.80, a price-to-sales ratio of about 12.84, and an enterprise value to sales ratio of 12.84 [5] - The enterprise value to operating cash flow ratio is around 12.73, and the earnings yield is approximately 6.76% [5]